The B7 family and cancer therapy: Costimulation and coinhibition

Xingxing Zang, James P. Allison

Research output: Contribution to journalReview article

248 Scopus citations

Abstract

The activation and development of an adaptive immune response is initiated by the engagement of a T-cell antigen receptor by an antigenic peptide-MHCcom plex. The outcome of this engagement is determined by both positive and negative signals, costimulation and coinhibition, generated mainly by the interaction between the B7 family and their receptor CD28 family. The importance of costimulation and coinhibition of T cells in controlling immune responses is exploited by tumors as immune evasion pathways. Absence of the expression of costimulatory B7 molecules renders tumors invisible to the immune system, whereas enhanced expression of inhibitory B7 molecules protects them from effective T cell destruction. Therefore, the manipulation of these pathways is crucial for developing effective tumor immunotherapy. Translation of our basic knowledge of costimulation and coinhibition into early clinical trials has shown considerable promise.

Original languageEnglish (US)
Pages (from-to)5271-5279
Number of pages9
JournalClinical Cancer Research
Volume13
Issue number18
DOIs
StatePublished - Sep 15 2007
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'The B7 family and cancer therapy: Costimulation and coinhibition'. Together they form a unique fingerprint.

  • Cite this